Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival ...

Hand-foot syndrome (HFS) is a dose-limiting adverse event associated with capecitabine, which leads to dose reductions and impairs the quality of life (QOL). In this double-blind, placebo-controlled ...

The common side effect of hand-foot syndrome seen in patients taking capecitabine can be prevented by a cheap and safe topical gel containing 1% diclofenac, researchers reported in a study that ...

Hand-foot syndrome is a severe skin reaction caused by some chemotherapy drugs, including Xeloda. It affects the soles of your feet, the palms of your hands, or both.

Context Certain chemotherapy drugs, notably capecitabine, can cause a side effect known as palmar-plantar erythrodysesthesia (hand-foot syndrome), a painful swelling and inflammation of the hands ...

In contrast, patients treated with Xeloda alone were more likely to develop hand-foot syndrome (swelling, redness and pain of the hands and feet) compared with those treated with tesetaxel plus Xeloda ...

The CNIO researchers found that patients who developed hand-foot syndrome during chemotherapy with capecitabine carried these regulatory variants that resulted in the reduced expression of CDH4 ...

The hand–foot syndrome, the most common adverse reaction to capecitabine, occurred in 73.4% of the patients in the capecitabine group.

Breast cancer patients receiving capecitabine had a lower incidence of hand-foot syndrome after prophylactic treatment with atorvastatin and polyprenol.